Table 1.
Baseline characteristics [4]
| Placeboa (n = 131) | Ritlecitinib QD | |||||
|---|---|---|---|---|---|---|
| 10 mg (n = 63) | 30 mg (n = 132) | 50 mg (n = 130) | 200/30 mg (n = 130) | 200/50 mg (n = 132) | ||
| Age | ||||||
| Mean (SD), years | 34.0 (15.0) | 34.3 (13.9) | 33.7 (14.8) | 32.4 (13.4) | 33.7 (13.8) | 34.5 (15.0) |
| 12–17 y, n (%) | 19 (14.5) | 9 (14.3) | 20 (15.2) | 18 (13.8) | 19 (14.6) | 20 (15.2) |
| ≥18 y, n (%) | 112 (85.5) | 54 (85.7) | 112 (84.8) | 112 (86.2) | 111 (85.4) | 112 (84.8) |
| Female, n (%) | 86 (65.6) | 43 (68.3) | 80 (60.6) | 71 (54.6) | 85 (65.4) | 81 (61.4) |
| Race, n (%) | ||||||
| White | 94 (71.8) | 42 (66.7) | 91 (68.9) | 79 (60.8) | 90 (69.2) | 92 (69.7) |
| Asian | 31 (23.7) | 17 (27.0) | 34 (25.8) | 43 (33.1) | 28 (21.5) | 33 (25.0) |
| Black or African American | 4 (3.1) | 2 (3.2) | 3 (2.3) | 5 (3.8) | 7 (5.4) | 6 (4.5) |
| Multiracial | 2 (1.5) | 0 | 2 (1.5) | 1 (0.8) | 3 (2.3) | 0 |
| American Indian or Alaska Native | 0 | 0 | 2 (1.5) | 0 | 1 (0.8) | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 (1.6) | 0 | 0 | 0 | 0 |
| Not reported | 0 | 1 (1.6) | 0 | 2 (1.5) | 1 (0.8) | 1 (0.8) |
| Severity of AA, n (%) | ||||||
| AT/AUb | 60 (45.8) | 29 (46.0) | 61 (46.2) | 60 (46.2) | 60 (46.2) | 60 (45.5) |
| Baseline SALT score, mean (SD) | ||||||
| Non-AT/AUb | 87.0 (12.9) | 78.3 (17.6) | 81.5 (16.3) | 82.0 (15.9) | 82.4 (15.4) | 82.2 (16.5) |
| Duration of current AA episode, mean (SD), years | 3.2 (2.7) | 3.3 (2.7) | 3.6 (2.8) | 3.2 (2.7) | 3.4 (2.9) | 3.4 (2.9) |
AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis; QD, once daily; SALT, Severity of Alopecia Tool.
aPlacebo alone for 24 weeks (and later switched to ritlecitinib).
bPatients in the AT/AU category had a SALT score of 100% at baseline as assessed by the investigator (regardless of the category in the AA history case report form).